Verdiperstat is under clinical development by Biohaven and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase III drugs for Amyotrophic Lateral Sclerosis have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Verdiperstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Verdiperstat (AZD-3241) is under development for the treatment of multiple system atrophy, amyotrophic lateral sclerosis, semantic variant primary progressive aphasia (svPPA) due to TDP-43 pathology. The drug candidate is orally administered and formulated in the form of capsules and tablets. It is a new chemical entity. The drug candidate acts by targeting myeloperoxidase (MPO). It was also under development for the treatment of Parkinson's disease.
Biohaven formerly Biohaven Research, is biopharmaceutical company discovering, developing, and commercializing novel therapies for the treatment of neurological and neuropsychiatric diseases. Biohaven is headquartered in Tortola, British Virgin Islands.
For a complete picture of Verdiperstat’s drug-specific PTSR and LoA scores, buy the report here.